Aradigm/Novo Nordisk Inhaled Insulin Manufacturing Issues Appear Resolved
This article was originally published in The Pink Sheet Daily
Executive Summary
Concerns over cosmetic blemishes on liquid insulin strips had delayed initiation of additional Phase III trials. Aradigm sees increased interest in its AERx pulmonary delivery system in the wake of Pfizer’s recent optimism about Exubera.
You may also be interested in...
Oralin Buccal Insulin May Face Easier Regulatory Path Than Inhaled Insulins, Generex Consultant Predicts
Oralin exposes only the oral cavity to insulin, Generex consultant Fleming says. Generex will pursue international approvals first with a more limited data package than FDA requires. Phase IIb trials have started in type 2 diabetes.
PTC’s Upstaza Takes Gene Therapy Straight To Brain (And US FDA); Translarna To Return Mid-Year
In a year full of regulatory milestones for the firm, PTC Therapeutics hopes to set some approval precedents – and basically hopes its candidates have an easier time of it than they have had before.
BeiGene’s Tevimbra And The End Of The COVID Inspection Era
US FDA approves the PD-1 inhibitor 20 months after user fee goal, resolving one of the last applications delayed by China’s extended pandemic travel restrictions.